E. Thunnissen Et Al. , "ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.," Lung cancer (Amsterdam, Netherlands) , vol.138, pp.13-18, 2019
Thunnissen, E. Et Al. 2019. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.. Lung cancer (Amsterdam, Netherlands) , vol.138 , 13-18.
Thunnissen, E., Lissenberg-Witte, B., van den Heuvel, M. M., Monkhorst, K., Skov, B. G., Sorensen, J. B., ... Mellemgaard, A.(2019). ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.. Lung cancer (Amsterdam, Netherlands) , vol.138, 13-18.
Thunnissen, E. Et Al. "ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.," Lung cancer (Amsterdam, Netherlands) , vol.138, 13-18, 2019
Thunnissen, E. Et Al. "ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.." Lung cancer (Amsterdam, Netherlands) , vol.138, pp.13-18, 2019
Thunnissen, E. Et Al. (2019) . "ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.." Lung cancer (Amsterdam, Netherlands) , vol.138, pp.13-18.
@article{article, author={E. Thunnissen Et Al. }, title={ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.}, journal={Lung cancer (Amsterdam, Netherlands)}, year=2019, pages={13-18} }